electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10
03 mars 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Stroke
09 févr. 2022 08h00 HE
|
electroCore, Inc.
Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J.,...
electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus
01 févr. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the TRANSIT...
electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022
25 janv. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible...
AudioSense Hearing, Balance & Concussion Celebrates Move to a New Exciting Location and Expanding Team
21 janv. 2022 09h00 HE
|
AudioSense Hearing, Balance & Concussion
Toronto, Jan. 21, 2022 (GLOBE NEWSWIRE) -- An estimated 1.5 billion people across the globe experience some level of difficulty with their hearing, today. Hearing loss is an invisible disability,...
gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)
12 janv. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received...
electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store
11 janv. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients...
electroCore Announces Publication of PREMIUM II Trial of gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine
10 janv. 2022 16h01 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper,...
electroCore to Present at H.C. Wainwright BIOCONNECT Virtual Conference
04 janv. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, NJ, Jan. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will...
electroCore, Inc. Provides Update on Global Distribution Partners
16 déc. 2021 08h00 HE
|
electroCore, Inc.
ROCKAWAY, NJ, Dec. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements...